Although systemic amyloidosis commonly presents with renal disease, cardiac involvement usually determines the patient's prognosis. Cardiac involvement is seen in light chain amyloid and transthyretin amyloidosis. Distinguishing between these two is critical because prognosis and treatment differ. Our study demonstrates the unreliability of transthyretin immunostaining in subtyping cardiac amyloid. Between January 2003 and August 2010, we retrieved 229 native endomyocardial biopsies, of which 24 had amyloid. Immunohistochemistry for k, l, transthyretin, and serum amyloid A protein was performed on formalin-fixed, paraffinembedded sections. Staining was graded as weak (trace to 1+) or strong (2 to 3+). Mass spectrometry (MS)-based proteomic typing of microdissected amyloid material was performed on selected cases. Fifteen patients had monoclonal gammopathy/plasma cell dyscrasia with cardiac amyloid. Eight of them (53%) showed strong transthyretin staining in the cardiac amyloid deposits. MS was performed in 5 of these 8 biopsies, and all 5 biopsies revealed light chain amyloid-type amyloid. Two of these 5 light chain amyloid biopsies did not even have concomitant strong staining for the appropriate light chain. Among the 15 cases with plasma cell dyscrasia, only 7 biopsies showed strong staining for the corresponding monoclonal light chain. Strong, false-positive immunostaining for transthyretin in cardiac amyloid is a potential pitfall, augmented by the frequent lack of staining for immunoglobulin light chains. Therefore, the presence of amyloid in the cardiac biopsy should prompt a search for plasma cell dyscrasia irrespective of transthyretin staining. Confirmation with MS should be sought, particularly if there is any discrepancy between k/l staining and serum immunofixation results.
A lthough systemic amyloidosis often presents first with kidney disease (proteinuria and renal dysfunction), cardiac involvement often determines the patient's prognosis. It is the most serious complication in patients with systemic amyloidosis and the cause of death in more than half of all cases. 4, 14 Systemic amyloidosis can be classified into 3 broad types: light chain amyloid (AL) (monoclonal light chain) amyloid, AA amyloid, and familial forms of amyloid. It is known that the prevalence of different types of amyloidosis varies with geographic location. However, what is less known is that different organs may have a different predilection for the various amyloid types. In kidney biopsies, AL-type amyloid is the most common, followed by AA-type amyloid (depending on the geographic location). Hereditary forms of amyloid, although rare, do involve the kidney; among these, fibrinogen A a chain-derived amyloid is the most common. 12 Transthyretin amyloid rarely affects the kidney. According to published studies, cardiac amyloidosis is of AL type in 54% of cases and of transthyretin type in 42% of cases. 2, 7 AA-type amyloid is rarely seen in the heart. 4, 5 Transthyretin amyloid in the heart can be either senile cardiac amyloidosis (due to acquired changes in the wild-type transthyretin molecule) or a familial form due to inherited mutations in transthyretin. Therefore, in native heart endomyocardial biopsies with amyloidosis, classifying the amyloid into AL type versus transthyretin type is critical. AL-type amyloidosis (affecting the heart) is an aggressive disease. Median survival rate has been reported to be 13 months without treatment and can be extended to 17 months with chemotherapy. 4 Cardiac involvement denotes a poor prognosis, regardless of the method of treatment. Median survival rate from the onset of congestive heart failure is only 6 months. 3, 4 Senile transthyretin amyloidosis carries the most favorable prognosis, with a nearly 5-year median survival rate even in the presence of heart failure. 4 Transthyretin mutations are associated with familial amyloidotic polyneuropathy, especially in endemic areas. In addition, they can cause cardiac amyloidosis as well. 15 The prognosis in familial transthyretin amyloidosis depends on the type of mutation and on the severity of cardiac involvement. 3, 6, 15 Importantly, specific treatment strategies including stem cell transplant have become the standard of care in AL-type amyloid. No known effective treatment is available for senile or familial transthyretin amyloid, other than cardiac transplantation.
Immunostaining is the first step in classifying amyloid, and this method is known to have pitfalls due to weak staining, nonspecific staining, and sometimes lack of staining, 1, 5, 9, 11, 13 paving the way for new proteomic techniques such as liquid chromatography and tandem mass spectrometry (LC MS/MS). 11, 16 Most of the previous studies dealing with immunostaining for amyloid subtyping have been conducted on kidney biopsies. However, the amyloid types involving the heart and the related pitfalls in staining provide a different challenge for the surgical pathologist. The aims of this study were to assess the prevalence of AL versus transthyretin amyloid subtypes in endomyocardial biopsies and to highlight the potentially misleading results of transthyretin staining in combination with k and l light chain staining.
MATERIALS AND METHODS
From January 2003 to August 2010, we examined 229 native endomyocardial biopsies. Congo red staining is routinely performed on every native heart biopsy. Biopsies of 24 patients were diagnosed as cardiac amyloidosis. All of the biopsies with amyloid were immunostained for k and l light chains, transthyretin, and serum amyloid A protein. Immunostaining for transthyretin (or prealbumin) was routinely performed from 2006 onward. Biopsies performed before 2006 were retrospectively stained for transthyretin for the purpose of this study. Staining for all 4 antibodies was performed on formalin-fixed, paraffin-embedded tissue sections using the immunoperoxidase method (see below under Antibodies and Staining Protocol section). Staining of the amyloid deposits was graded as weak (trace to 1+) or strong (2 to 3+) (Figs. 1A-D). For 5 of the cases (cases 16, 17, 18, 19 , and 20 in Table 1 ), LC MS/MS confirmation of amyloid type was performed at the Mayo Clinic, Rochester, MN. For one of the biopsies (case 8, before Mayo Clinic accepted specimens for LC MS/MS), the paraffin block was sent to the laboratory of Dr Alan Solomon at Knoxville, TN, for MS analysis 10 ; however, results on this biopsy were inconclusive because of the small amount of tissue remaining in the paraffin block.
Antibodies and Staining Protocol
Immunoperoxidase staining was performed on formalin-fixed, paraffin-embedded tissue sections. Antibody for transthyretin (prealbumin) is a rabbit polyclonal antibody (Dako; A0002), used at a dilution of 1:1200 with Dako's LSAB detection kit. Immunoperoxidase staining for k and l light chains was performed using mouse monoclonal antibodies from DAKO (Carpinteria, CA) at a dilution of 1:8 and 1:16, respectively. All immunoperoxidase staining was performed on the DAKO Autostainer. The control tissue used for transthyretin staining was an autopsy case of cardiac transthyretin amyloid.
LC MS/MS
Paraffin blocks, along with 1 hematoxylin and eosinstained slide and Congo red-stained slide, were sent to Dr Ahmet Dogan at the Mayo Clinic, Rochester, MN. The MS analysis was performed according to published protocols. 17 
RESULTS
Patients ranged in age from 57 to 80 years; 15 were male, and 9 were female. Three of the patients were of african american, and the rest of the patients were caucasian.
Fifteen of 24 patients showed serologic evidence of monoclonal gammopathy: 10 patients with monoclonal l light chains, 4 patients with monoclonal k light chains, and 1 with IgG heavy chains (Table 1) . Seven patients had overt myeloma, and 1 patient had Waldenstro¨m macroglobulinemia. One patient (case 8) had histiocytic sarcoma of the head and neck. He had IgG heavy chain gene rearrangement but no free monoclonal light chains in the serum or urine. The amyloid in this case stained for IgG heavy chain (specifically for IgG1); staining for k and l light chains was weak. The small tissue left in the paraffin block was inadequate for MS analysis. Therefore, the nature of this amyloid could not be confirmed by LC MS/MS, but the patient's tumor did show a favorable response to chemotherapy. For the purpose of this study, he was included among the patients with monoclonal gammopathy.
Of the 15 biopsies from patients with monoclonal gammopathy, 8 showed strong (2 to 3+) positivity for transthyretin in the amyloid deposits (cases 8, 9, 12, 16, 17, 18, 19, and 20) . Of these 8 biopsies with strong transthyretin staining, 4 had concomitant strong (2 to 3+) staining for the appropriate light chain (cases 9, 12, 17, and 20); however, the remaining 4 biopsies (cases 8, 16, 18, and 19) did not ( Figs. 2A-D) . These results are shown in Table 2 . LC MS/MS confirmation of AL-type amyloid was obtained for cases 16, 17, 18, 19 , and 20. Mass spectrometry was attempted on case 8, but tissue was inadequate. Table 2 , among the 9 patients with cardiac amyloid and without proven plasma cell dyscrasia, 7 biopsies did show strong transthyretin staining as expected; 1 showed weak staining, and 1 did not have diagnostic tissue left. In addition, 3 biopsies showed strong staining for one of the light chains (concomitant with transthyretin staining). Two patients were confirmed as having familial form of transthyretin amyloid (Ala 60 mutation confirmed by blood test performed at the laboratory of Prof PN Hawkins, National Amyloidosis Center Royal Free Hospital, London, UK). The remain-ing 7 of 9 patients without monoclonal gammopathy, were treated as senile transthyretin amyloidosis ( Table 3 ). The sensitivity, specificity, and predictive values of positive and negative staining for transthyretin and immunoglobulin light chains are shown in Table 4 .
As shown in

DISCUSSION
Cardiac amyloidosis is most commonly of the AL type or of the transthyretin type. 7 Our study confirms this prevalence pattern. AA-type amyloid is uncommon in the United States, and rare hereditary forms including fibrinogen A a chain amyloid, apolipoprotein AI and AII amyloid, gelsolin, lysozyme, and so on have not been reported in the heart. Transthyretin amyloid can be either senile cardiac amyloidosis due to amyloidogenic wild-type transthyretin or familial/hereditary amyloid due to inherited transthyretin mutations. 3, 4, 6, 7, 15 Although the age of presentation for both AL and transthyretin amyloidosis is similar (fifth to sixth decade), the disease prognosis differs greatly. AL-type amyloidosis is an aggressive disease with poor long-term patient outcome. In contrast, senile cardiac amyloidosis is a more indolent disease. In familial type transthyretin amyloidosis, prognosis may vary according to the type of mutation. Therefore, on endomyocardial biopsies with amyloid, the critical step is to be able to differentiate between AL-type amyloid and transthyretintype amyloid.
Immunostaining is the most readily available technique in the hands of a surgical pathologist for subtyping amyloid. However, it is known that immunostaining of amyloid is fraught with problems. These include: (i) falsenegative results due to weak staining or even lack of staining, often seen with commercial antibodies to k and l light chains 11, 16 due to the presence of truncated light chains in AL-type amyloid deposits; and (ii) false-positive results due to nonspecific immunostaining of the amyloid deposits. Strong diffuse homogeneous staining of amyloid deposits for any of the precursor proteins would usually be interpreted as a positive result by the pathologist. However, we want to draw attention to the fact that, even when the staining is strong and diffuse, it can be nonspecific (false positive). This is illustrated in our study by the strong distinct (false positive) transthyretin staining of amyloid deposits in several of the endomyocardial biopsies when the amyloid is AL type.
We found 8 of 15 such biopsies with strong, falsepositive transthyretin staining among patients with plasma cell dyscrasia and monoclonal gammopathy in our retrospective study. Five of the biopsies were sent for MS analysis and were confirmed as AL-type amyloid. Some of these patients did not have a diagnosis of monoclonal gammopathy at the time of the cardiac biopsy but were subsequently worked up for it and were found to have a plasma cell dyscrasia. It would have been ideal if all these cases had been tested by LC MS/MS for confirmation; however, the technique is expensive, and, this being a retrospective study, the results would not have improved patient care at this point. In addition, endomyocardial biopsies are small, and much of the tissue may have been cut away from the paraffin block by the time the diagnosis of amyloid was made. We found a positive predictive value of only 46.6% for transthyretin immunostaining in our study.
The problem of weak immunoperoxidase staining for k and l light chains is known, primarily from the literature on renal amyloidosis. 9, 11 We found a sensitivity of just 46.6% in our study for light chain staining in patients with confirmed AL amyloidosis. It can range from as low as 38% to 65% 9,11 (in kidney biopsies with amyloid), necessitating a high index of suspicion and better correlation with clinical manifestations, imaging studies, and sensitive immunoassays to detect circulating free monoclonal light chains.
Low sensitivity for light chain staining and concomitant false-positive staining for transthyretin together constitute a diagnostic problem. The clinical relevance of this is that AL-type amyloid (which is the more aggressive but potentially treatable form of systemic amyloid) can be missed. One may argue that antibodies from different sources may give different staining results. Although this is true, the question arises which antibody is ideal for use in routine diagnostic immunohistochemistry. One cannot keep changing them from case to case. The antibody concentration used is somewhat high, but the staining obtained is very specific and restricted to the areas of amyloid. There is no nonspecific background staining away from the area of amyloid deposition. Further, the control tissue used is an autopsy case of transthyretin amyloid, which is very appropriate. The sensitivity of the transthyretin stain was found to be 87.5% in our study. There are not too many histopathologic studies specifically looking at transthyretin immunostaining, but 1 previous study 8 also showed high sensitivity of staining in cardiac amyloid. It has to be emphasized that the specificity of transthyretin immunostaining in cardiac amyloid is low, and it is necessary to be aware of the high rate of false-positive results. The cause of the strong nonspecific transthyretin staining in cardiac amyloid is not known. One hypothesis is that the contractile activity of the heart and the disturbance of the normal architecture by amyloid can support the diffusion of serum proteins such as transthyretin (prealbumin) into amyloid deposits, and these will be detected on immunostaining. 7 Nonspecific staining of amyloid can be seen even in the kidney for immunoreactants such as IgG, suggesting that the amyloid material itself is "sticky" and has a tendency to nonspecifically trap serum proteins either in vivo or in vitro. 16 Because of the above pitfalls, LC MS/MS has now become a new gold standard for the typing of amyloid; however, it is still an expensive test. Nevertheless, if there is any discrepancy between the immunofixation test results and tissue light chain staining results, or if there is serologic evidence of monoclonal gammopathy but strong immunostaining for transthyretin in the amyloid deposits, it is imperative to send biopsy tissues for amyloid subtyping by LC MS/MS.
In summary, distinguishing AL from transthyretin amyloid in cardiac biopsies is crucial. Immunostaining is still the most commonly used method. However, the pathologist has to be aware of the potential pitfalls. Strong transthyretin staining can occur in AL-type amyloid (and often with weak concomitant light chain staining), and this is obviously misleading. Therefore, it is important that after the diagnosis of amyloidosis in an endomyocardial biopsy (or in any other tissue), irrespective of the staining pattern, the patient should undergo workup for monoclonal gammopathy and plasma cell dyscrasia. Serum and urine protein electrophoresis with immunofixation are recommended. If these tests are negative or inconclusive, a more sensitive quantitative free light chain assay is recommended. However, on the other hand, a coincidental serum monoclonal spike as seen in monoclonal gammopathy of unknown significance, can simultaneously be present, which by itself does not prove that the amyloid is of the AL type. It should coincide with appropriate light chain staining in the amyloid deposits in tissue. Corresponding monoclonal free light chains in urine is also important to investigate. It is important that the monoclonal light chain in the serum (and urine) and the monoclonal light chain staining in the tissue amyloid deposits match.
In the presence of amyloid deposits in the biopsy, irrespective of the immunostaining results, the possibility of AL-type amyloid should be first convincingly ruled out by investigating the patient for possible plasma cell dyscrasia. This should be done even if the immunostaining for k/l light chains is weak/absent and is strong for transthyretin.
